Insulet Corp. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Insulet Corp. has submitted its annual 10-K filing for the fiscal year 2023, detailing its financial performance and business operations.</b>

AI Summary

INSULET CORP (PODD) filed a Annual Report (10-K) with the SEC on February 23, 2024. Insulet Corp. filed its 10-K report for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal business address is 100 Nagog Park, Acton, MA 01720. Insulet Corp. is incorporated in Delaware. The Standard Industrial Classification code for the company is 3841 (Surgical & Medical Instruments & Apparatus).

Why It Matters

For investors and stakeholders tracking INSULET CORP, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Insulet Corp.'s financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed financial information and risk factors disclosed in the 10-K are essential for investors and stakeholders to make informed decisions regarding their investments in Insulet Corp. (PODD).

Risk Assessment

Risk Level: medium — INSULET CORP shows moderate risk based on this filing. The company operates in the medical device industry, which is subject to significant regulatory oversight and rapid technological advancements, posing potential risks to its market position and financial performance.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Insulet Corp.'s performance and potential challenges in the medical device market.

Key Numbers

• 2023-12-31 — Fiscal Year End (CONFORMED PERIOD OF REPORT)
• 2024-02-23 — Filing Date (FILED AS OF DATE)
• 3841 — SIC Code (STANDARD INDUSTRIAL CLASSIFICATION)

Key Players & Entities

• INSULET CORP (company) — FILER
• 0001145197 (company) — ACCESSion NUMBER
• 20231231 (date) — CONFORMED PERIOD OF REPORT
• 20240223 (date) — FILED AS OF DATE
• 100 NAGOG PARK (address) — BUSINESS ADDRESS
• ACTON (city) — BUSINESS ADDRESS
• MA (state) — BUSINESS ADDRESS
• 01720 (zip) — BUSINESS ADDRESS

FAQ

Industry Context

Insulet Corp. operates in the medical device industry, specifically focusing on diabetes care technology. This sector is characterized by innovation, regulatory scrutiny, and a growing demand for advanced treatment solutions.

Regulatory Implications

The medical device industry is subject to stringent regulations from bodies like the FDA. Companies must adhere to quality standards, manufacturing practices, and post-market surveillance requirements to ensure product safety and efficacy.

What Investors Should Do

1. Review Insulet Corp.'s detailed financial statements for the fiscal year 2023.
2. Analyze the risk factors section to understand potential challenges and uncertainties.
3. Compare key financial metrics with previous years to identify trends and performance changes.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
• 2024-02-23: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This filing represents the annual 10-K for the fiscal year 2023, providing a comprehensive update compared to previous filings which would include quarterly reports (10-Q) and potentially other material event disclosures.

Key Financial Figures

• $0.001 — ange on Which Registered Common Stock, $0.001 Par Value Per Share PODD The NASDAQ Sto

Filing Documents

• podd-20231231.htm (10-K) — 2075KB
• podd-exx1033_20231231x10k.htm (EX-10.33) — 27KB
• podd-exx1056_20231231x10k.htm (EX-10.56) — 338KB
• podd-exx1057_20231231x10k.htm (EX-10.57) — 20KB
• podd-exx1058_20231231x10k.htm (EX-10.58) — 16KB
• podd-exx1059_20231231x10k.htm (EX-10.59) — 119KB
• podd-exx1064_20231231x10k.htm (EX-10.64) — 16KB
• podd-exx211_20231231x10k.htm (EX-21.1) — 13KB
• podd-exx231_20231231x10k.htm (EX-23.1) — 2KB
• podd-exx311_20231231x10k.htm (EX-31.1) — 9KB
• podd-exx312_20231231x10k.htm (EX-31.2) — 10KB
• podd-exx321_20231231x10k.htm (EX-32.1) — 7KB
• podd-exx971_20231231x10k.htm (EX-97.1) — 12KB
• podd-20231231_g1.jpg (GRAPHIC) — 1795KB
• podd-20231231_g2.jpg (GRAPHIC) — 1533KB
• podd-20231231_g3.jpg (GRAPHIC) — 25KB
• podd-20231231_g4.jpg (GRAPHIC) — 136KB
• 0001145197-24-000011.txt (&nbsp;) — 21978KB
• podd-20231231.xsd (EX-101.SCH) — 86KB
• podd-20231231_cal.xml (EX-101.CAL) — 133KB
• podd-20231231_def.xml (EX-101.DEF) — 522KB
• podd-20231231_lab.xml (EX-101.LAB) — 1143KB
• podd-20231231_pre.xml (EX-101.PRE) — 855KB
• podd-20231231_htm.xml (XML) — 2013KB

Risk Factors

Item 1A Risk Factors 15

Unresolved Staff Comments

Item 1B Unresolved Staff Comments 28 Item 1C Cybersecurity 28

Properties

Item 2 Properties 29

Legal Proceedings

Item 3 Legal Proceedings 29

Mine Safety Disclosures

Item 4 Mine Safety Disclosures 29 PART II

Market for Registrant ' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5 Market for Registrant ' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 30

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 7 Management ' s Discussion and Analysis of Financial Condition and Results of Operations 32

Quantitative and Qualitative Disclosures About Market Risk

Item 7A Quantitative and Qualitative Disclosures About Market Risk 41

Financial Statements and Supplementary Data

Item 8 Financial Statements and Supplementary Data 42

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 77

Controls and Procedures

Item 9A Controls and Procedures 77

Other Information

Item 9B Other Information 81 PART II I

Directors, Executive Officers and Corporate Governance

Item 10 Directors, Executive Officers and Corporate Governance 81

Executive Compensation

Item 11 Executive Compensation 81

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 81

Certain Relationships and Related Transactions, and Director Independence

Item 13 Certain Relationships and Related Transactions, and Director Independence 81

Principal Accounting Fees and Services

Item 14 Principal Accounting Fees and Services 81 PART I V

Exhibits, Financial Statement Schedules

Item 15 Exhibits, Financial Statement Schedules 82

Form 10-K Summary

Item 16 Form 10-K Summary 86

SIGNATURES

SIGNATURES 87 Table of Contents PART I

Business

Item 1. Business Overview Insulet Corporation ("we" or the "Company") is primarily engaged in the development, manufacture and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod 5 Automated Insulin Delivery System ("Omnipod 5"), the Omnipod DASH Insulin Management System ("Omnipod DASH"), the Omnipod Insulin Management System ("Classic Omnipod") and our latest innovation, Omnipod GO TM , which received U.S. Food and Drug Administration ("FDA") clearance in 2023. We also produce pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta to help reduce the risk of infection after intense chemotherapy. Market Opportunity: Management of Diabetes Diabetes is a chronic, life-threatening disease for which there is no known cure. It is caused by the body's inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels. Glucose, the primary source of energy for cells, must be maintained at certain concentrations in the blood in order to permit optimal cell function and health. In people with diabetes, blood glucose levels fluctuate between very high levels, a condition known as hyperglycemia, and very low levels, a condition called hypoglycemia. Hyperglycemia can lead to serious short-term complications, such as confusion, vomiting, dehydration, and loss of consciousness and long-term complications, such as blindness, kidney disease, nervous system disease, occlusive vascular diseases, stroke, cardiovascular disease, or death. Hypoglycemia can lead to confusion, loss of consciousness, or death. Diabetes is typically classified as either type 1 or type 2: Type 1 diabetes is characterized by the body's nearly complete inability to produce insulin. It is frequently diagnosed during childhood or adolescence. Individuals with type 1 diabetes require daily insulin therapy to su

View Full Filing

View this 10-K filing on SEC EDGAR